Yet another study has found that medical cannabis access could be a tool in curbing the national opioid epidemic as University of Georgia researchers observed a 14.4 percent reduction in prescription opioid use in states with medical cannabis dispensaries and another 7 percent reduction in such prescriptions in states with home-cultivation-only medical cannabis laws, according to a Science Daily report.
The study by the University of Georgia, School of Public and International Affairs, was published Apr. 2 in the Journal of the American Medical Association, Internal Medicine. Researchers examined the number of all opioid prescriptions filled between 2010 and 2015 under Medicare Part D, which is the prescription drug plan available to Medicare enrollees. The study looked at common prescription opioids, including hydrocodone, oxycodone, morphine, methadone, and fentanyl.
W. David Bradford, study co-author and Busbee chair in public policy for the UGA school, indicated that the researchers were asking “what happens to physician behavior in terms of their opiate prescribing if and when medical cannabis becomes available” noting that some of the states analyzed by researchers had medical cannabis laws throughout